Bready's Healthcare Presents Blood Biomarker and Digital Healthcare Research at ASAD

Bredhis Healthcare garnered significant attention by announcing innovative research achievements for the early diagnosis and prevention of dementia at the Asian Society Against Dementia (ASAD), Asia's largest academic conference dedicated to dementia. Held in Seoul from May 8th to 10th under the theme 'Beyond the Limits of Dementia: From Research to Real-world Application', this ASAD served as an authoritative platform where Asian dementia experts convened to discuss the latest research and treatment strategies. At this conference, Bredhis Healthcare unveiled two major research findings. The first was a study on blood biomarkers for the early diagnosis of Alzheimer's disease. Based on empirical data from over 1,000 individuals, the study comprehensively analyzed phosphorylated tau 217 (pTau217) alongside biomarkers related to neuroinflammation and neurodegeneration. It proposed a method to maximize diagnostic accuracy by also considering demographic factors such as age. This research is particularly noteworthy as it significantly increased the clinical applicability of diagnosing Alzheimer's disease through blood tests. The second study was an in-depth analysis of factors influencing the acceptance of digital healthcare technologies for the early diagnosis and prevention of dementia in the elderly. It investigated factors affecting the acceptance of both complementary technologies, which assist existing healthcare systems, and transformative technologies, which provide new experiences related to healthcare, among healthy elderly individuals. The research team suggested that customized application strategies, tailored to the characteristics of the technology, could open a new paradigm in elderly healthcare. Meanwhile, Bredhis Healthcare possesses unique technological capabilities, being the only entity in the world to provide ultra-high sensitivity biomarker analysis, including SIMOA analysis, in a cleanroom environment that complies with Global Clinical Laboratory Practice (GCLP) guidelines. CEO Gina Kim stated, "A significant portion of blood biomarker research analyses from major Asian research institutions, including the National University of Singapore (NUS), have been performed by Bredhis Healthcare," emphasizing, "We will continue to deepen our research into dementia diagnosis and prevention based on our global-standard research infrastructure."